Physician profile

Leon D Mclaughlin

Family Medicine · Daphne, AL

NPI 1649286188

$1,764.10

in general payments reported to CMS, 2019-2025

24 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Lilly USA, LLC $241.49 2019-2020
Astrazeneca Pharmaceuticals LP $233.30 2019-2020
Novo Nordisk INC $219.32 2019-2020
Amgen INC. $210.20 2019-2020
Abbvie INC. $88.97 2021-2022
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $87.89 2019
Pfizer INC. $82.96 2019
Mylan Specialty L.P. $71.99 2019
Astellas Pharma US INC $69.28 2019-2020
Shire North American Group INC $67.93 2019
Boehringer Ingelheim Pharmaceuticals, INC. $60.68 2019-2020
Novartis Pharmaceuticals Corporation $49.07 2019
Ironshore Pharmaceuticals INC. $41.62 2019
Takeda Pharmaceuticals U.S.A., INC. $41.41 2019-2020
Neos Therapeutics, LP $37.92 2019-2020
Show all 24 companies
CompanyGeneral paymentsYearsTop products
Daiichi Sankyo INC. $28.62 2019-2020
Avanir Pharmaceuticals, INC. $23.62 2019
Amarin Pharma, INC. $19.27 2020
Otsuka America Pharmaceutical, INC. $19.27 2019
Teva Pharmaceuticals USA, INC. $17.54 2019
Sanofi Pasteur INC. $14.63 2019
Allergan, INC. $14.07 2020
Hikma Pharmaceuticals USA $12.00 2019
Supernus Pharmaceuticals, INC. $11.05 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Leon D Mclaughlin

$1,764.10

in general payments reported 2019-2025

Years
2019-2022
Top company
Lilly USA, LLC

https://glasscript.com/doctor/165499/leon-d-mclaughlin

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.